Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · IEX Real-Time Price · USD
3.300
+0.300 (10.00%)
At close: Mar 28, 2024, 4:00 PM
3.340
+0.040 (1.21%)
After-hours: Mar 28, 2024, 7:59 PM EDT
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MREO stock have an average target of 6.50, with a low estimate of 6.00 and a high estimate of 7.00. The average target predicts an increase of 96.97% from the current stock price of 3.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MREO stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +112.12% | Mar 28, 2024 |
Needham | Needham | Strong Buy Maintains $5 → $6 | Strong Buy | Maintains | $5 → $6 | +81.82% | Mar 28, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +112.12% | Mar 22, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $4 | Buy | Reiterates | $4 | +21.21% | Sep 8, 2023 |
Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +51.52% | Sep 8, 2023 |
Financial Forecast
Revenue This Year
8.09M
Revenue Next Year
22.29M
from 8.09M
Increased by 175.45%
EPS This Year
-0.04
from -0.30
EPS Next Year
-0.02
from -0.04
Revenue Forecast
Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | 10.5M | 91.8M | n/a | 27.4M | 56.0M | 94.9M |
Avg | 8.1M | 22.3M | n/a | 26.6M | 54.4M | 92.2M |
Low | 7.0M | n/a | n/a | 25.6M | 52.3M | 88.6M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | 1,034.2% | - | - | 110.6% | 74.3% |
Avg | - | 175.5% | - | - | 104.6% | 69.3% |
Low | - | - | - | - | 96.5% | 62.7% |
EPS Forecast
EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -0.04 | 0.07 | -0.05 | -0.05 | -0.05 | -0.05 |
Avg | -0.04 | -0.02 | -0.06 | -0.05 | -0.05 | -0.05 |
Low | -0.05 | -0.06 | -0.06 | -0.05 | -0.05 | -0.05 |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | - | - |
Avg | - | - | - | - | - | - |
Low | - | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.